ArticleCurrent oncology (Toronto, Ont.)2022

A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors.

Nagla Abdel Karim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.